Estrogens in polycystic liver disease: A target for future therapies?
Sophie E AapkesLucas H P BerntsThijs R M BartenMarjan van den BergRon T GansevoortJoost Paulus Hubertus DrenthPublished in: Liver international : official journal of the International Association for the Study of the Liver (2021)
Based on the available evidence, female PLD patients should be discouraged from taking estrogen-containing contraceptives or hormone replacement therapy. Since liver growth rates decline after menopause, treatment decisions should be based on measured liver growth in postmenopausal women. Finally, blockage of estrogen receptors or estrogen production is a promising target for new therapies.